Acadia Healthcare Is Maintained at Buy by TD Cowen
Acadia Healthcare Co Analyst Ratings
KeyBanc Upgrades Acadia Healthcare to Overweight From Sector Weight, Sets $70 Price Target
TD Cowen Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Cuts Target Price to $66
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
Deutsche Bank Upgrades Acadia Healthcare Co to Buy, Raises Price Target to $75
Deutsche Bank Upgrades Acadia Healthcare(ACHC.US) to Buy Rating, Raises Target Price to $75
Deutsche Bank Upgrades Acadia Healthcare to Buy From Hold, Adjusts Price Target to $75 From $45
Cantor Fitzgerald Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Cuts Target Price to $52
Acadia Healthcare Co Analyst Ratings
Cantor Fitzgerald Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Cuts Target Price to $52
TD Cowen Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Cuts Target Price to $70
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Acadia Healthcare (ACHC) and Bicara Therapeutics Inc. (BCAX)
Barclays Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Maintains Target Price $43
Mizuho Securities Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Announces Target Price $48
Acadia Healthcare Is Maintained at Overweight by Barclays
Barclays Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Cuts Target Price to $43
Barclays Reaffirms Their Buy Rating on Acadia Healthcare (ACHC)
Deutsche Bank Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Maintains Target Price $45
RBC Capital Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Announces Target Price $64